Comparison of pediatric and adult trials including adolescents in their study populations
| Trial . | Years . | Study age range, y . | Adolescent age range, y . | N . | CR, % . | HSCT, % . | EFS, % (y) . | DFS, % (y) . | OS, % (y) . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| FRALLE 93 | 1993-1999 | 0-20 | 15-20 | 77 | 94 | 17 | 67 (5) | 72 (5) | 78 (5) | 6 |
| LALA 94 | 1994-2000 | 15 to adult | 15-20 | 100 | 83 | 9 | 41 (5) | 49 (5) | 45 (5) | |
| CCG 1882-1901 | 1989-1995 | 0-21 | 16-20 | 197 | 90 | 3 | 63 (7) | NR | 67 (7) | 42 |
| CALGB | 1988-1998 | 16 to adult | 16-20 | 124 | 90 | 1 | 34 (7) | NR | 46 (7) | |
| AIEOP ALL 95, 2000 | 1996-2003 | 0-18 | 14-18 | 150 | 94 | NR | NR | NR | 80 (2) | 43 |
| GIMEMA ALL 0496, 2000 | 1996-2003 | 14 to adult | 14-18 | 95 | 89 | NR | NR | NR | 71 (2) | |
| DCOG 6-9 | 1985-1999 | 0-18 | 15-18 | 47 | 98 | 4 | 69 (5) | 71 (5) | NR | 44 |
| HOVON ALL 5, 18 | 1985-1999 | 15 to adult | 15-18 | 44 | 91 | 25 | 34 (5) | 37 (5) | NR | |
| NOPHO | 1992-2000 | 0-18 | 15-20 | 36 | 99 | NR | 74 (5) | NR | NR | 45 |
| SAALLG | 1994-2000 | 15-40 | 15-20 | 23 | 90 | NR | 39 (5) | NR | NR | |
| MRC ALL97/99 | 1997-2002 | 0-17 | 15-17 | 61 | 98 | 13 | 65 (5) | NR | 71 (5) | 46 |
| UKALL XII/E2993 | 1997-2002 | 15-55 | 15-17 | 67 | 94 | 30 | 49 (5) | NR | 56 (5) |
| Trial . | Years . | Study age range, y . | Adolescent age range, y . | N . | CR, % . | HSCT, % . | EFS, % (y) . | DFS, % (y) . | OS, % (y) . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| FRALLE 93 | 1993-1999 | 0-20 | 15-20 | 77 | 94 | 17 | 67 (5) | 72 (5) | 78 (5) | 6 |
| LALA 94 | 1994-2000 | 15 to adult | 15-20 | 100 | 83 | 9 | 41 (5) | 49 (5) | 45 (5) | |
| CCG 1882-1901 | 1989-1995 | 0-21 | 16-20 | 197 | 90 | 3 | 63 (7) | NR | 67 (7) | 42 |
| CALGB | 1988-1998 | 16 to adult | 16-20 | 124 | 90 | 1 | 34 (7) | NR | 46 (7) | |
| AIEOP ALL 95, 2000 | 1996-2003 | 0-18 | 14-18 | 150 | 94 | NR | NR | NR | 80 (2) | 43 |
| GIMEMA ALL 0496, 2000 | 1996-2003 | 14 to adult | 14-18 | 95 | 89 | NR | NR | NR | 71 (2) | |
| DCOG 6-9 | 1985-1999 | 0-18 | 15-18 | 47 | 98 | 4 | 69 (5) | 71 (5) | NR | 44 |
| HOVON ALL 5, 18 | 1985-1999 | 15 to adult | 15-18 | 44 | 91 | 25 | 34 (5) | 37 (5) | NR | |
| NOPHO | 1992-2000 | 0-18 | 15-20 | 36 | 99 | NR | 74 (5) | NR | NR | 45 |
| SAALLG | 1994-2000 | 15-40 | 15-20 | 23 | 90 | NR | 39 (5) | NR | NR | |
| MRC ALL97/99 | 1997-2002 | 0-17 | 15-17 | 61 | 98 | 13 | 65 (5) | NR | 71 (5) | 46 |
| UKALL XII/E2993 | 1997-2002 | 15-55 | 15-17 | 67 | 94 | 30 | 49 (5) | NR | 56 (5) |
Modified and updated from Ramanujachar et al.46
AIEOP, Associazione Italiana di Ematologia e Oncologia Pediatrica; CALGB, Cancer and Leukemia Group B; CCG, Children’s Cancer Group; CR, complete remission; DCOG, Dutch Childhood Oncology Group; DFS, disease-free survival; FRALLE, French Acute Lymphoblastic Leukemia Study Group; GIMEMA, Gruppo Italiano Malattie EMatologiche dell'Adulto; HOVON, Hemato-Oncologie voor Volwassenen Nederland; LALA, Leucémies Aiguës Lymphoblastiques de l’Adulte; MRC, Medical Research Council; NR, not reported; SAALLG, Swedish Adult ALL Group; UKALL, United Kingdom Acute Lymphoblastic Leukaemia.